The British Association of Dermatologists' Biologic Interventions Register (BADBIR): Design, methodology and objectives

British Journal of Dermatology

Volumn 166, Issue 3, 2012, Pages 545-554

  Burden, A D ^a   Warren, R B ^b   Kleyn, C E ^b   McElhone, K ^b   Smith, C H ^c   Reynolds, N J ^d,e   Ormerod, A D ^f   Griffiths, C E M ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ROYAL VICTORIA INFIRMARY   (United Kingdom)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ACTIVITY; DISEASE REGISTRY; HUMAN; INFECTION; MEDICAL SOCIETY; PRIORITY JOURNAL; PSORIASIS; SKIN CANCER; UNITED KINGDOM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOLOGICAL AGENTS; DATA COLLECTION; DERMATOLOGIC AGENTS; DERMATOLOGY; GREAT BRITAIN; HUMANS; IRELAND; ORGANIZATIONAL OBJECTIVES; PATIENT SAFETY; PATIENT SELECTION; PHARMACOVIGILANCE; PSORIASIS; REGISTRIES; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 84863164660     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10835.x     Document Type: Article

References (23)

1. Gelfand JM, Berlin J, van Voorhees A, Margolis DJ,. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425-9. (Pubitemid 37433132)
2. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126: 2194-201. (Pubitemid 44413165)
3. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-30. (Pubitemid 38461682)
4. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-72. (Pubitemid 27452539)
5. Gladman DD, Farewell DT, Hong K, Husted J,. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103-10. (Pubitemid 28265412)
6. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211-16. (Pubitemid 36513069)
7. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-12. (Pubitemid 29333701)
8. Stern RS, Lunder EJ,. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-5. (Pubitemid 29009260)
9. Lim JL, Stern RS,. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 2005; 124: 505-13. (Pubitemid 40381572)
10. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
11. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
12. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50. (Pubitemid 351509656)
13. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis; a randomised trial. Lancet 2001; 357: 1842-7. (Pubitemid 32539117)
14. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32. (Pubitemid 37523083)
15. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
16. Leonardi C, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74. (Pubitemid 351671883)
17. Wathion N,. European Medicines Agency Public Statement on Raptiva (Efalizumab). 2009. Available at: (last accessed 5 January 2012).
18. Gliklich RE, Dreyer NA, (eds). Registries for Evaluating Patient Outcomes: A User's Guide, 2nd edn. AHRQ Publication No. 10-EHC049. Rockville, MD: Agency for Healthcare Research and Quality, 2010.
19. Wolk K, Mallbris L, Larsson P, et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol (Stockh) 2009; 89: 492-7.
20. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37: 1386-94.
21. Lecluse LL, Naldi L, Stern RS, Spuls PI,. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218: 347-56.
22. Burden AD, Hilton Boon M, Leman J, et al. Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. BMJ 2010; 341: c5623.
23. Watson K, Symmonds D, Griffiths I, Silman A,. The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005; 64: iv42-3. (Pubitemid 41532016)